Results 51 to 60 of about 408 (149)

T‐Cell Immunity and Lung Cancer

Respirology, Volume 31, Issue 3, Page 236-249, March 2026.
ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley   +1 more source

Comparison of IL‐2‐antibody to IL‐2‐Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors

Cancer Medicine
Background The potent immune effects of interleukin‐2 (IL‐2) for cancer therapy can be increased by genetic fusion of IL‐2 to the Fc domain of an antibody (IL‐2‐Fc) or tumor targeted by genetic fusion to a whole antibody known as an immunocytokine (ICK).
Lindsay Williams, Lin Li, Paul J. Yazaki, Patty Wong, Teresa Hong, Erasmus K. Poku, Susanta Hui, Hemendra Ghimire, John E. Shively, Maciej Kujawski   +9 more
doaj   +1 more source

Immunotherapy for Leiomyosarcoma: Current Status and Perspectives

Journal of Immunology Research, Volume 2026, Issue 1, 2026.
Leiomyosarcoma (LMS), one of the soft‐tissue sarcomas (STSs), has a relatively higher risk of distant metastasis. This has resulted in current first‐line treatments still failing to deliver satisfactory outcomes, and the current treatment of LMS remains controversial and challenging.
Haoyue Qi, Hanxi Zhang, Qin Wang, Xiaolu Wang, Limei Min, Yingling Zhou, Baorui Liu, Rutian Li, Poorani Gurumallesh   +8 more
wiley   +1 more source

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy [PDF]

, 2019
Antibody-cytokine fusion proteins ("immunocytokines”) represent a promising class of armed antibody products, which allow the selective delivery of potent pro-inflammatory payloads at the tumor site. The antibody-based selective delivery of interleukin-2
Castioni, Nadia, Pretto, Francesca, Elia, Giuliano, Neri, Dario   +3 more
core  

Anti-CD70-IFN-γ immunocytokines exert RIP1-dependent necrotic activity on RCC cell lines.

, 2013
(A) RenCa, Caki-1, 786-O, or HRC63 cells were co-treated with bortezomib (MTD) and, respectively, murine (RenCa) or human (Caki-1, 786-O, and HRC63) IFN-γ immunocytokines (‘Anti-CD70 fusion’, 50 ng/ml) in the presence or absence of 50 μM RIP1 kinase ...
Peirong Chen (403320), Shoko Nogusa (347948), Heidi Simmons (403323), Gregory P. Adams (269450), Siddharth Balachandran (66976), Calvin Shaller (403322), Suraj Peri (70543), Roshan J. Thapa (403321)   +7 more
core   +1 more source

Advances in IL–15–Based Cancer Immunotherapy and Divergent Immunological Effects of IL–2 and IL–15 Signaling via the Shared IL–2Rβγ Receptor

Frontiers in Immunology
Interleukin-15 (IL-15) has emerged as a central cytokine for next-generation cancer immunotherapy because of its unique ability to sustain the survival, proliferation, and cytotoxic function of memory CD8+ T cells and natural killer (NK) cells without ...
Huiquan Gao, Tao Ma, Qinqin Jiang, Lanfang Gao, Jinfang Li, Shubo Wang, Ziyong Liu, Zhixin Zhang, Gang Wu, Wenxin He, Fuxin Zhou   +10 more
doaj   +1 more source

Crosstalk Between Cancer‐Associated Fibroblasts and Immune Cells: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 4, Issue 4, December 2025.
Cancer‐associated fibroblasts (CAFs) are widely engaged in tumor progression in the tumor microenvironment. CAFs interact actively with immunocytes including tumor‐associated macrophages, T cells, neutrophils, and NK cells in a positive‐feedback loop to sculpt tumor immune microenvironment and participate in tumor activities and antitumor therapy ...
Ya Li, Xingpeng Di, Jiawei Chen, Jingwen Wei, Tianyue Li, Kunjie Wang, Banghua Liao, Deyi Luo   +7 more
wiley   +1 more source

Combination Therapy of Immunocytokines with Ipilimumab: A Cure for Melanoma? [PDF]

Journal of Investigative Dermatology, 2013
Although biological therapy has shown promising clinical responses in many cancers including metastatic melanoma, only a subset of patients has shown marked regression of lesions. In most patients, systemic administration of biological therapies with cytokines is associated with severe toxicities.
Wang, Tao, Somasundaram, Rajasekharan, Herlyn, Meenhard   +2 more
openaire   +2 more sources

Generation and purification of mIFN-γ and hIFN-γ immunocytokines targeting CD70.

, 2013
(A) Two plasmids – pMAZ-IgH and pMAZ-IgL – were used as backbones to construct and express anti-CD70 immunocytokines bearing either murine (m) or human (h) IFN-γ.
Peirong Chen (403320), Shoko Nogusa (347948), Heidi Simmons (403323), Gregory P. Adams (269450), Siddharth Balachandran (66976), Calvin Shaller (403322), Suraj Peri (70543), Roshan J. Thapa (403321)   +7 more
core   +1 more source

Spatial multiomics to inform immunocytokine engineering: knowledge base, gaps, and QC solutions

Frontiers in Immunology
Systemic pro-inflammatory cytokine therapies (e.g., IL-2) represented early milestones in immunotherapy, but their use is hampered by low response rates and severe off-target toxicity.
Priyank Patel, Luke Daniel Batty, Marina Bleck, Shyam Nathan   +3 more
doaj   +1 more source